Clinical Trials List
2022-03-28 - 2025-12-31
Phase I
Not yet recruiting2
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Wei-Wu Chen Division of Hematology & Oncology
- MING-YANG WANG Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 羅喬 Division of Hematology & Oncology
- 林季宏 Division of Hematology & Oncology
- WEI-LI MA Division of Hematology & Oncology
- 張端瑩 Division of Hematology & Oncology
- 黃柏翔 Division of Hematology & Oncology
- 林柏翰 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
7 participants
-
Global
202 participants
